EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Retrograde Cricopharyngeal Dysfunction: Patient Characteristics and Outcomes in Australia

Zhou Hao Leong iD, Sarah Emmett, Katrina Sandham, Thomas Stewart, Daniel Novakovic iD

ANZ Journal of Surgery · 2026

DOI: 10.1111/ans.70518 ↗

At a glance

Journal article in ANZ Journal of Surgery, 2026. Written by Zhou Hao Leong and 4 co-authors. Institution: University of Sydney Voice Research Laboratory, Discipline of Speech Pathology, Faculty of Medicine and Health, The University of Sydney, Sydney, New…. Major MEDLINE topics: Botulinum Toxins, Type A, Deglutition Disorders, Pharyngeal Muscles, Neuromuscular Agents. 11 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Retrograde cricopharyngeal dysfunction (RCPD) is characterised by an inability to burp. Typical first‐line management involves injection of Botulinum A toxin (BonT‐A) into the cricopharyngeus. We present our series of 109 RCPD patients.

Methods

A retrospective chart review was conducted between January 2018 and November 2024. Demographics and clinical data were extracted. From late 2021 onwards, we also started collecting scores from a 7‐point Likert questionnaire based on the six cardinal symptoms of RCPD (RCPD‐Q in short).

Results

A109 patients were identified. Sixty‐two (56.9%) were female. Mean age was 30.0 (range: 14–72). The majority (91.7%) were of Caucasian ethnicity. Eighty patients completed the RCPD‐Q at their initial consultation, with a mean score of 27.6/36 (range: 13–36). Seventy‐four patients underwent initial treatment. At first follow‐up within 4 weeks, 53 patients (71.6%) had complete resolution, 11 (14.9%) had partial resolution and seven (9.5%) had no change in symptoms. In the 30 patients who completed follow‐up at > 3 months after treatment, 17 patients (56.7%) reported complete resolution, three patients (10%) reported partial resolution and 10 patients (33.3%) reported no resolution or reversion to baseline symptoms.

Conclusion

Younger age, treatment under general anaesthesia, and higher doses of BonT‐A were associated with higher rates of success. Level of Evidence Level 3.

Subjects

MeSH terms (MEDLINE)

Botulinum Toxins, Type ADeglutition DisordersPharyngeal MusclesNeuromuscular AgentsHumansFemaleRetrospective StudiesAdultMiddle AgedMaleAustraliaAgedAdolescentTreatment OutcomeYoung Adult

Author keywords

botulinum toxinno burpretrograde cricopharyngeal dysfunction

Substances

Botulinum Toxins, Type ANeuromuscular Agents

Authors and institutions

  • University of Sydney Voice Research Laboratory, Discipline of Speech Pathology, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Otolaryngology, The Canterbury Hospital, Campsie, New South Wales, Australia.

ORCID profiles: Zhou Hao Leong, Daniel Novakovic

Cite

APA

Leong, Z. H., Emmett, S., Sandham, K., Stewart, T., & Novakovic, D. (2026). Retrograde Cricopharyngeal Dysfunction: Patient Characteristics and Outcomes in Australia. ANZ Journal of Surgery. https://doi.org/10.1111/ans.70518

Vancouver

Leong ZH, Emmett S, Sandham K, Stewart T, Novakovic D. Retrograde Cricopharyngeal Dysfunction: Patient Characteristics and Outcomes in Australia. ANZ Journal of Surgery. 2026. doi:10.1111/ans.70518

BibTeX
@article{Leong2026,
  author = {Leong, Zhou Hao and Emmett, Sarah and Sandham, Katrina and Stewart, Thomas and Novakovic, Daniel},
  title = {Retrograde Cricopharyngeal Dysfunction: Patient Characteristics and Outcomes in Australia},
  journal = {ANZ Journal of Surgery},
  year = {2026},
  doi = {10.1111/ans.70518}
}
Start for free →